This finding suggests that there is less of a possibility of a genomic copy number gain such as that which underlies the over-expression of several other molecules, including c-ERBB-2, Cyclin-D1, AURKA, and GATA6 in pancreatic cancer [48], [49]. Here, CCND1 is linked to pancreatic neoplasm.